GlassScriptPhysician profile
Daniel Joseph Donofrio
NPI 1710090915
$5,709.82
in general payments reported to CMS, 2019-2025
42 companies · $663 in 2025
The $663 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $292 · 2021: $300 · 2022: $976 · 2023: $1,271 · 2024: $1,354 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,287.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,271.57 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $388.74 | 2019-2025 | Spravato |
| Abbvie INC. | $375.63 | 2021-2025 | Vraylar |
| Pfizer INC. | $314.37 | 2022-2025 | |
| Abbott Laboratories | $290.60 | 2019-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $254.05 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $246.65 | 2019-2025 | Airsupra, Flumist Quadrivalent, Evusheld |
| Boston Scientific Corporation | $232.20 | 2019-2024 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $215.99 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $206.83 | 2022-2023 | |
| Medtronic, INC. | $170.95 | 2022-2025 | Symplicity G3, Interstim, Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.10 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $152.19 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Scientific Affairs, LLC | $136.34 | 2019 | |
| Axogen | $127.49 | 2023 | Avance Nerve Graft |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Donofrio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.